December 12, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bolt Biotherapeutics, Inc. (“Bolt” or “the Company”) (NASDAQ: BOLT). Investors who purchased Bolt securities prior to February 5, 2021, and continue to hold to the present, are encouraged to obtain additional… read more
December 12, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paladin Energy Ltd (“Paladin” or “the Company”) (OTCMKTS: PALAF). Investors who purchased Paladin securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Paladin has violated… read more
December 11, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XPEL, Inc. (“XPEL” or “the Company”) (NASDAQ: XPEL). Investors who purchased XPEL securities prior to November 8, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more
December 11, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Vicor Corporation (“Vicor” or “the Company”) (NASDAQ: VICR). Investors who purchased Vicor securities prior to April 26, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more
December 11, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Malibu Boats, Inc. (“Malibu Boats” or “the Company”) (NASDAQ: MBUU). Investors who purchased Malibu Boats securities prior to November 4, 2022, and continue to hold to the present, are encouraged to… read more
December 11, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Equinix, Inc. (“Equinix” or “the Company”) (NASDAQ: EQIX). Investors who purchased Equinix securities prior to May 3, 2019, and continue to hold to the present, are encouraged to obtain additional information… read more
December 11, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of EngageSmart, Inc. (“EngageSmart” or “the Company”) (NYSE: ESMT). Investors who purchased EngageSmart securities prior to October 23, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more
December 11, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Domino’s Pizza, Inc. (“Domino’s” or “the Company”) (NYSE: DPZ). Investors who purchased Domino’s securities prior to December 7, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
December 11, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Direct Digital Holdings Inc. (“Direct Digital” or “the Company”) (NASDAQ: DRCT). Investors who purchased Direct Digital securities prior to April 17, 2023, and continue to hold to the present, are encouraged… read more
December 11, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dick’s Sporting Goods, Inc. (“Dick’s” or “the Company”) (NYSE: DKS). Investors who purchased Dick’s securities prior to May 25, 2022, and continue to hold to the present, are encouraged to obtain… read more
December 11, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. (“BioVie” or “the Company”) (NASDAQ: BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information… read more
December 11, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. (“Amylyx” or “the Company”) (NASDAQ: AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional… read more
December 11, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. (“Akero” or “the Company”) (NASDAQ: AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional… read more
December 9, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Five Below, Inc. (“Five Below” or “the Company”) (NASDAQ: FIVE). Investors who purchased Five Below securities prior to December 1, 2022, and continue to hold to the present, are encouraged to… read more
December 9, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Silvaco Group, Inc. (“Silvaco” or “the Company”) (NASDAQ: SVCO). Investors who purchased Silvaco securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Silvaco has violated… read more
December 9, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Pactiv Evergreen Inc. (“Pactiv Evergreen”) (NASDAQ: PTVE) and Novolex®. Investors who purchased Pactiv Evergreen and continue to hold to the present are encouraged to obtain additional information and assist the investigation. Investigation Details The investigation… read more
December 6, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Franklin Resources, Inc. (“Franklin” or “the Company”) (NYSE: BEN). Investors who purchased Franklin securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Franklin has violated… read more
December 4, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Orthofix Medical Inc. (“Orthofix” or “the Company”) (NASDAQ: OFIX). Investors who purchased Orthofix securities prior to October 11, 2022, and continue to hold to the present, are encouraged to obtain additional… read more
December 4, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sprinklr, Inc. (“Sprinklr” or “the Company”) (NYSE: CXM). Investors who purchased Sprinklr securities prior to March 29, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more
December 2, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. (“Avid”) (NASDAQ: CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation…. read more
December 2, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Steel Connect, Inc. (“Steel Connect”) (NASDAQ: STCN) and Steel Partners Holdings L.P. (“Steel Partners”). Investors who purchased Steel Connect and continue to hold to the present are encouraged to obtain additional information and assist the… read more
November 25, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Macy’s, Inc. (“Macy’s” or “the Company”) (NYSE: M). Investors who purchased Macy’s securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Macy’s has violated federal… read more
November 25, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Macy’s, Inc. (“Macy’s” or “the Company”) (NYSE: M). Investors who purchased Macy’s securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Macy’s has violated federal… read more
November 22, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation (“Quanterix” or “the Company”) (NASDAQ: QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Quanterix has violated federal… read more
November 21, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Oklo Inc. (“Oklo” or “the Company”) (NYSE: OKLO). Investors who purchased Oklo securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Oklo has violated federal… read more
November 20, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. (“Spyre” or “the Company”) (NASDAQ: SYRE). Investors who purchased Spyre securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Spyre has violated… read more
November 13, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. (“Neurogene” or “the Company”) (NASDAQ: NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Neurogene has violated federal… read more
November 5, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Extreme Networks, Inc. (“Extreme Networks” or “the Company”) (NASDAQ: EXTR). Investors who purchased Extreme Networks securities prior to July 27, 2022, and continue to hold to the present, are encouraged to… read more
October 31, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DZS, Inc. (“DZS” or “the Company”) (NASDAQ: DZSI). Investors who purchased DZS securities prior to March 10, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more
October 30, 2024 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Janus International Group, Inc. (“Janus” or “the Company”) (NYSE: JBI). Investors who purchased Janus securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Janus has… read more